Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform

Dow Jones

06/09

By Adriano Marchese

Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis.

Shares traded 25% higher ahead of the morning bell at $7.35.

The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases.

The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year.

The company also said the partnership provides a framework to move additional programs into human testing more efficiently.

Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 09, 2026 08:59 ET (12:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2642498856"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642498856\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642498856?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642498856","market":"sh","top_or_hot":-1,"title":"Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n</p>\n<p>\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n</p>\n<p>\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n</p>\n<p>\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n</p>\n<p>\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n</p>\n<p>\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 08:59 ET (12:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCartesian Therapeutics Shares Rise on Licensing Deal for WestGene Delivery Platform\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-09 20:59</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n</p>\n<p>\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n</p>\n<p>\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n</p>\n<p>\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n</p>\n<p>\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n</p>\n<p>\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 08:59 ET (12:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAC","symbol_name":"Cartesian Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642498856","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642498856","pubTimestamp":1781009940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis.Shares traded 25% higher ahead of the morning bell at $7.35.The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases.The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year.The company also said the partnership provides a framework to move additional programs into human testing more efficiently.Under the terms of the agreement, WestGene will rec","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNAC":"Cartesian Therapeutics","BK4139":"生物科技"},"translate_title":"Cartesian Therapeutics股价因WestGene递送平台许可协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAC":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune diseases, starting with myasthenia gravis. \n\n\n  Shares traded 25% higher ahead of the morning bell at $7.35. \n\n\n  The late-clinical-stage company on Tuesday said it entered into a strategic licensing agreement with WestGene to advance the development of novel in vivo chimeric antigen receptor T-cell therapies, also known as CAR-T, in autoimmune diseases. \n\n\n  The partnership pairs Cartesian's mRNA CAR-T payloads with WestGene's delivery system to enable in-vivo CAR-T generation. The company said there is a planned Phase 1 trial for the treatment of myasthenia gravis, a chronic autoimmune disorder, slated for the second half of this year. \n\n\n  The company also said the partnership provides a framework to move additional programs into human testing more efficiently. \n\n\n  Under the terms of the agreement, WestGene will receive an unspecified upfront payment and is also eligible for development and commercial milestone payments. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 08:59 ET (12:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}